HARS1: A Potential Drug Target and Biomarker (G3035)

Target Name: HARS1

NCBI ID: G3035

HARS1

HARS1: A Potential Drug Target and Biomarker

Hepatitis B virus (HBV) is a viral infection that affects millions of people worldwide and is a leading cause of liver cancer, cirrhosis, and other serious health complications. The Hepsin A (HARS1) gene is a potential drug target and biomarker for HBV, and its research has the potential to lead to new treatments for this debilitating and often fatal disease.

Hepsin A is a non-coding RNA molecule that is expressed in the liver and other tissues. It is a key regulator of the immune response and has been shown to play a role in the development and progression of HBV infection.

Research has shown that HARS1 is involved in the replication of both positive and negative viruses. It has been shown to regulate the expression of several key genes involved in the immune response, including the interferon response and the antiviral response.

HARS1 has also been shown to be involved in the regulation of the viral replication cycle. It has been shown to interact with the viral protein NS1 and to play a role in the assembly and disassembly of the virus's genome.

In addition to its role in virus replication, HARS1 has also been shown to be involved in the regulation of cell signaling pathways. It has been shown to interact with the protein PDGF, which is a key regulator of cell signaling pathways.

The potential drug target for HARS1 is the use of small molecules, such as drugs that can modulate the activity of HARS1, to treat HBV infection. This approach is being actively explored as a potential treatment for HBV and has the potential to significantly improve the treatment outcomes for patients.

Hepsin A has also been shown to be a potential biomarker for HBV infection. The level of HARS1 expression in the liver can be used as a marker for the presence and severity of HBV infection. This approach has the potential to improve the accuracy and speed of HBV diagnosis and treatment.

Overall, the research on HARS1 has the potential to lead to new treatments for HBV and to improve the quality of life for patients with this debilitating and often fatal disease. Further research is needed to fully understand the role of HARS1 in HBV infection and to develop effective treatments.

Protein Name: Histidyl-tRNA Synthetase 1

Functions: Catalyzes the ATP-dependent ligation of histidine to the 3'-end of its cognate tRNA, via the formation of an aminoacyl-adenylate intermediate (His-AMP) (PubMed:29235198). Plays a role in axon guidance (PubMed:26072516)

The "HARS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HARS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets